These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8642565)

  • 1. Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability.
    Lehr P; Billich A; Charpiot B; Ettmayer P; Scholz D; Rosenwirth B; Gstach H
    J Med Chem; 1996 May; 39(10):2060-7. PubMed ID: 8642565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.
    Ettmayer P; Billich A; Hecht P; Rosenwirth B; Gstach H
    J Med Chem; 1996 Aug; 39(17):3291-9. PubMed ID: 8765512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
    Bold G; Fässler A; Capraro HG; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Acemoglu F; Beck W; Boss E; Eschbach M; Hürlimann T; Masso E; Roussel S; Ucci-Stoll K; Wyss D; Lang M
    J Med Chem; 1998 Aug; 41(18):3387-401. PubMed ID: 9719591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
    J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
    J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.
    Scholz D; Billich A; Charpiot B; Ettmayer P; Lehr P; Rosenwirth B; Schreiner E; Gstach H
    J Med Chem; 1994 Sep; 37(19):3079-89. PubMed ID: 7932531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
    Abdel-Rahman HM; el-Koussi NA; Alkaramany GS; Youssef AF; Kiso Y
    Arch Pharm (Weinheim); 2004 Nov; 337(11):587-98. PubMed ID: 15540219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
    Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
    Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of orthogonally protected (3R, 4S)- and (3S, 4S)-4,5-diamino-3-hydroxypentanoic acids.
    Czajgucki Z; Sowiński P; Andruszkiewicz R
    Amino Acids; 2003 Apr; 24(3):289-91. PubMed ID: 12707811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746.
    Franchetti P; Perlini P; Abu Sheikha G; Cappellacci L; Grifantini M; Loi AG; De Montis A; Pani A; Marongiu ME; La Colla P
    Antivir Chem Chemother; 1998 Jul; 9(4):303-9. PubMed ID: 9875409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.